Language：English   Publishing type：Research paper (scientific journal)   Publisher：Internal Medicine  

Objective To explore the opinions of outpatients concerning a new communication method: the selfmanagement of assessed personal problems in health information records (SAPPHIRE) using patients' mobile phones to store and share medical content (medical SAPPHIRE, or m-SAPPHIRE). Methods A cross-sectional questionnaire survey. Patients Outpatients who visited us from March 1 to May 30, 2012, were asked to complete a questionnaire survey regarding SAPPHIRE and m-SAPPHIRE. The m-SAPPHIRE data consisted of a problem list, height, weight, waist size and active medication list. Ten questions were asked regarding the usefulness of m- SAPPHIRE, the sharing of m-SAPPHIRE and the use of mobile phones to store m-SAPPHIRE data. Results One hundred and ninety-three patients (male/female, 79/114; mean age, 57±21 years) were registered: 95.9% answered that m-SAPPHIRE would be useful, 98% agreed to manage their personal health records by themselves, and 95.8%, 93.8%, and 92.8% of the patients responded that they would allow m- SAPPHIRE information to be shared with family members, medical workers, and health care providers, respectively. Of the patients, 75.1% responded that they owned a mobile phone, and 43.5% answered that they could enter m-SAPPHIRE information into a mobile phone by themselves, while 27.5% responded that they could do so with someone's help. Conclusion Patients believe that m-SAPPHIRE would be useful for retrieving their health records during emergency situations or for sharing with family members and medical and health care providers. SAPPHIRE using mobile phones could be an inexpensive and legal method for sharing medical data. © 2013 The Japanese Society of Internal Medicine.

DOI： 10.2169/internalmedicine.52.9030

Scopus

PubMed

Language：Japanese   Publishing type：Research paper (scientific journal)   Publisher：Granulocytes: Production, Types and Roles in Disease  

Scopus

Language：English   Publishing type：Research paper (scientific journal)   Publisher：Pediatric Blood and Cancer  

Background: Recent advances in multidisciplinary treatment approaches have improved the overall prognosis of pediatric brain tumors, but some patients remain refractory to treatment and do poorly. Several molecularly targeted therapies are under development for the treatment of brain tumors, and high-grade gliomas in adults are a particular area of study. Procedure: To better understand if these new therapies can be used in pediatric populations, we examined the expression of the following seven marker genes involved in signaling pathways targeted by new therapies: β-catenin, suppressor of fused (SUFU), erythroblastic leukemia viral oncogene homolog (ERBB) 2, platelet-derived growth factor receptorα (PDGFRα), proliferating cell nuclear antigen (PCNA), secreted protein acid and rich in cysteine (SPARC), and granulocyte colony-stimulating factor receptor (G-CSFR). Samples from 27 patients with the primitive neuroectodermal tumor (PNET)/medulloblastomas (MBs) (n=8), ependymomas (n=5), or gliomas (n=14) were assessed by quantitative real-time PCR. [Correction made here after initial online publication]. We assigned an EXP score to compare across samples and determined the levels of gene expression among tumor cell types. Results: Gene expression varied among the different tumors, but, within a tumor type, clear expression patterns were seen. The expression of SUFU, ERBB2, and PCNA in metastatic MBs were greater than that seen in non-metastatic MBs. Most glioma cases highly expressed PDGFRα and G-CSFR. Additionally, the expression patterns of gliomas and ependymomas were similar (r=0.77, P=0.04), but PNET/MBs substantially differed from gliomas (r=-0.37, P=0.41) or ependymomas (r=0.23, P=0.62). Conclusions: The development of new drugs targeting up-regulated pathways may be useful for the treatment of pediatric brain tumors. As new drugs are developed, gliomas and ependymomas may be treated with similar compounds. © 2011 Wiley Periodicals, Inc.

DOI： 10.1002/pbc.23009

Web of Science

Scopus

PubMed

Language：Japanese   Publishing type：Research paper (scientific journal)   Publisher：Basophil Granulocytes  

Scopus

Language：Japanese   Publishing type：Research paper (scientific journal)   Publisher：Japan Society of Ningen Dock  

<b>Objective:</b> We screened examinees with hypercalcemia in Ningen Dock for primary hyperparathyroidism.<br><b>Methods:</b> Examinees were screened from July 1995 to December 2010. Serum calcium (Ca), phosphate and albumin (Alb) were measured using an auto-analyzer. Examinees with hypercalcemia were selected for primary hyperparathyroidism screening and their serum Ca levels were adjusted using serum Alb levels to provide corrected serum calcium(cCa) levels. For those with high serum Ca and cCa levels, serum parathyroid hormone(PTH)levels were measured for diagnosis of primary hyperparathyroidism. We also investigated examinees from July 2001 to December 2010 regarding a relationship between primary hyperparathyroidism and hypercalcemia. <br><b>Results:</b> The total number of examinees was 1,936 (1,324 males, 612 females). The first case of serum high Ca and cCa levels was the 817th examinee since our Ningen Dock started, and the second was the 1,737th (920th case after first detected case). These 2 examinees were diagnosed with primary hyperparathyroidism due to high serum PTH levels. When we investigated 1,615 examinees during the period July 2001 to December 2010, high serum Ca levels were detected in 24 cases(1.5%). High serum cCa levels were detected in 3 cases, consisting of 2 cases of primary hyperparathyroidism and one of multiple myeloma. <br><b>Conclusions:</b> On screening for primary hyperparathyroidism in Ningen Dock examinees, we detected 2 cases of primary hyperparathyroidism. The first case was the 817th examinee and the second case the 1,737th examinee. The detection rate for hyperparathyroidism in Ningen Dock seems to be about 1/1,000.

DOI： 10.11320/ningendock.26.498

Language：Japanese

Basophilic granulocytes (basophils) are a very small population of peripheral blood leukocytes. Because basophils have high-affinity immunoglobulin E receptors (Fce{open}RI) and secrete chemical mediators that contain histamine, they are thought to be very similar to mast cells. However, research characterizing the function of basophils was slow to proceed and their unique function and importance were not established for a significant period of time. Recently, a series of studies have characterized the role of basophils in anaphylactic shock, chronic allergic reactions, and other human immunological reactions. These studies have shown that basophils are not a supplementary cell type but key players in very serious immune reactions. In this chapter we introduce the recently discovered characteristics of basophils. In addition, we consider how these aspects are clinically important and are connected with new cellular or molecular treatments for allergic reactions. © 2012 Nova Science Publishers, Inc. All rights reserved.

Scopus

Language：Japanese

Basophilic granulocytes (basophils) are a very small population of peripheral blood leukocytes. Because basophils have high-affinity immunoglobulin E receptors (Fc?RI) and secrete chemical mediators that contain histamine, they are thought to be very similar to mast cells. However, research characterizing the function of basophils was slow to proceed and their unique function and importance were not established for a significant period of time. Recently, a series of studies have characterized the role of basophils in anaphylactic shock, chronic allergic reactions, and other human immunological reactions. These studies have shown that basophils are not a supplementary cell type but key players in very serious immune reactions. In this chapter we introduce the recently discovered characteristics of basophils. In addition, we consider how these aspects are clinically important and are connected with new cellular or molecular treatments for allergic reactions. © 2011 Nova Science Publishers, Inc. All rights reserved.

Scopus